Gip 1 Agonist? You Probably Mean Tirzepatide: Quick Guide

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

Searches for "gip 1 agonist" almost always mean tirzepatide (tirzepatide, marketed under brand names Mounjaro (type 2 diabetes) and Zepbound (chronic weight management); also available through licensed compounding pharmacy pathways). This is a brief disambiguation post that explains what tirzepatide is, what it's FDA-approved for, and where to go from here.

What tirzepatide actually is

Tirzepatide is a GIP and GLP-1 dual receptor agonist marketed under brand names Mounjaro (type 2 diabetes) and Zepbound (chronic weight management); also available through licensed compounding pharmacy pathways. It is FDA-approved for type 2 diabetes (Mounjaro, 2022). Tirzepatide is administered as a once-weekly subcutaneous injection (FDA-approved formulation) per its FDA label. Per-month list price as of April 2026 is approximately $1,059–$1,069 per month at U.S. list price as of April 2026 (Eli Lilly published pricing for Zepbound and Mounjaro).

Key facts about tirzepatide

• Active ingredient: tirzepatide
• Manufacturer: marketed under brand names Mounjaro (type 2 diabetes) and Zepbound (chronic weight management); also available through licensed compounding pharmacy pathways
• FDA-approved indication: type 2 diabetes (Mounjaro, 2022)
• Format: once-weekly subcutaneous injection (FDA-approved formulation)
• List price (April 2026): approximately $1,059–$1,069 per month at U.S. list price as of April 2026 (Eli Lilly published pricing for Zepbound and Mounjaro)

Where this leaves you

If you were searching for tirzepatide: it is a real, FDA-approved GIP and GLP-1 dual receptor agonist available by prescription. The PlexusDx Weight Management Protocols collection includes the active ingredient (tirzepatide) through clinician-supervised compounded protocols. To start upstream with the genetic context, the Precision Peptide Genetic Test analyzes the GLP-1 pathway biology that sits underneath any of these decisions.

Upstream of any GLP-1 protocol decision, the PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in FTO, GLP1R, and MC4R that shape baseline GLP-1, appetite-regulation, and energy-balance biology. That genetic context is the test before you invest framing PlexusDx applies to every protocol conversation.

Related reading on PlexusDx: What Is GLP-1?, What Is GLP-1?, GLP-1 Receptor Agonist, GLP-1 Drugs.

Disclaimer: This article is educational. PlexusDx offers tirzepatide through its Weight Management Protocols — this article covers the mechanism, evidence, and genetic context that informs any decision to use it. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Learn more about the PlexusDx Tirzepatide protocol or the oral tirzepatide protocol inside the Weight Management Protocols collection. To start upstream with the genetic context, take the Precision Peptide Genetic Test first.

Frequently Asked Questions

Is "gip 1 agonist" the same as tirzepatide?

Yes — "gip 1 agonist" is a common misspelling or phonetic search variant of tirzepatide (tirzepatide, marketed under brand names Mounjaro (type 2 diabetes) and Zepbound (chronic weight management); also available through licensed compounding pharmacy pathways). It is the same medication. Tirzepatide is FDA-approved for type 2 diabetes (Mounjaro, 2022) and is administered as a once-weekly subcutaneous injection (FDA-approved formulation).

How is tirzepatide actually spelled?

Tirzepatide is the brand name; the active ingredient is tirzepatide, marketed under brand names Mounjaro (type 2 diabetes) and Zepbound (chronic weight management); also available through licensed compounding pharmacy pathways. Confusion with the spelling is common because the name is unusual. The FDA label and manufacturer materials use the spelling "tirzepatide".

Where can I learn more about tirzepatide?

The Mounjaro/Zepbound product website and the FDA label are the primary sources. The PlexusDx Education Hub also has explainer content on the GLP-1 receptor agonist class — including the tirzepatide active ingredient and the genetic pathways that underlie all GLP-1 protocol decisions.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education